Bone mineral density in children and adolescents with prader-willi syndrome: A Longitudinal study during puberty and 9 years of growth hormone treatment

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 4, 2015, Pages 1609-1618

  Bakker, N E ^a,b   Kuppens, R J ^a,b   Siemensma, E P C ^a,b   Tummers De Lind Van Wijngaarden, R F A ^a   Festen, D A M ^a   Bindels De Heus, G C B ^b   Bocca, G ^c   Haring, D A J P ^d   Hoorweg Nijman, J J G ^e   Houdijk, E C A M ^f   Jira, P E ^g   Lunshof, L ^h   Odink, R J ⁱ   Oostdijk, W ^j   Rotteveel, J ^k   Van Alfen, A A E M ^l   Van Leeuwen, M ^m   Van Wieringen, H ^e   Wegdam Den Boer, M E J ⁿ   Zwaveling Soonawala, N ^o   Hokken Koelega, A C S ^a,b   more..

^a Dutch Growth Research Foundation   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d Diaconessen Hospital   (Netherlands)

^e ST ANTONIUS HOSPITAL   (Netherlands)

^f JULIANA CHILDREN S HOSPITAL   (Netherlands)

^g JEROEN BOSCH HOSPITAL   (Netherlands)

^h GELRE HOSPITALS   (Netherlands)

ⁱ CATHARINA HOSPITAL   (Netherlands)

^j LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^k VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^l RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^m ST JANSDAL HOSPITAL   (Netherlands)

ⁿ Medical Center Twente   (Netherlands)

^o UNIVERSITY OF AMSTERDAM   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; GROWTH HORMONE; SOMATOMEDIN C; TESTOSTERONE; HUMAN GROWTH HORMONE; SEX HORMONE;

ADOLESCENT; AGE; ARTICLE; BODY HEIGHT; BODY MASS; BONE DENSITY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; DUTCHMAN; FEMALE; HUMAN; LEAN BODY WEIGHT; LONGITUDINAL STUDY; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; PRADER WILLI SYNDROME; PREDICTION; PREPUBERTY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBERTY; SCHOOL CHILD; SEX DIFFERENCE; SEXUAL DEVELOPMENT; TREATMENT DURATION; TREATMENT OUTCOME; BODY COMPOSITION; DRUG EFFECTS; NETHERLANDS; PATHOPHYSIOLOGY; PHYSIOLOGY; PRADER-WILLI SYNDROME; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; TIME;

ADOLESCENT; BODY COMPOSITION; BONE DENSITY; CHILD; CHILD, PRESCHOOL; FEMALE; GONADAL STEROID HORMONES; HUMAN GROWTH HORMONE; HUMANS; LONGITUDINAL STUDIES; MALE; NETHERLANDS; PRADER-WILLI SYNDROME; PUBERTY; TIME FACTORS;

EID: 84927597332     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-4347     Document Type: Article

References (42)

1. Holm VA, Cassidy SB, Butler MG, et al. Prader-Willi syndrome: Consensus diagnostic criteria. Pediatrics. 1993;91:398-402.
2. Bakker NE, Kuppens RJ, Siemensma EP, et al. Eight years of growth hormone treatment in children with prader-willi syndrome: Maintaining the positive effects. J Clin Endocrinol Metab. 2013;98:4013-4022.
3. Lindgren AC, Lindberg A. Growth hormone treatment completely normalizes adult height and improves body composition in Prader-Willi syndrome: Experience fromKIGS (Pfizer International Growth Database). Horm Res. 2008;70:182-187.
4. Festen DA, Wevers M, Lindgren AC, et al. Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome. Clin Endocrinol. 2008;68:919-925.
5. Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, et al. Beneficial effects of growth hormone treatment on cognition in children with Prader-Willi syndrome: A randomized controlled trial and longitudinal study. Clin Endocrinol Metab. 2012;97:2307-2314.
6. de Lind van Wijngaarden RF, Otten BJ, Festen DA, et al. High prevalence of central adrenal insufficiency in patients with Prader-Willi syndrome. Clin Endocrinol Metab. 2008;93:1649-1654.
7. Kido Y, Sakazume S, Abe Y, et al. Testosterone replacement therapy to improve secondary sexual characteristics and body composition without adverse behavioral problems in adult male patients with Prader-Willi syndrome: An observational study. AmJ Med GenetA. 2013;161:2167-2173.
8. Eldar-Geva T, Hirsch HJ, Pollak Y, Benarroch F, Gross-Tsur V. Management of hypogonadism in adolescent girls and adult women with Prader-Willi syndrome. AmJ Med GenetA. 2013;161A:3030-3034.
9. Ohlsson C, Isgaard J, Tornell J, et al. Endocrine regulation of longitudinal bone growth. Acta paediatrica. 1993;82(Suppl 391):33-40; discussion 41.
10. Zofkova I. Hormonal aspects of the muscle-bone unit. Physiol Res. 2008;1(57 Suppl);S159-S169.
11. Boot AM, de Ridder MA, van der Sluis IM, van Slobbe I, Krenning EP, Keizer-Schrama SM. Peak bone mineral density, lean body mass and fractures. Bone. 2010;46:336-341.
12. Salamat MR, Salamat AH, Abedi I, Janghorbani M. Relationship between Weight, Body Mass Index, and Bone Mineral Density in Men Referred for Dual-Energy X-Ray Absorptiometry Scan in Isfahan, Iran. J Osteoporos. 2013;2013:205963.
13. Edouard T, Deal C, Van Vliet G, et al. Muscle-bone characteristics in children with Prader-Willi syndrome. J Clin Endocrinol Metab. 2012;97:E275-E281.
14. de Lind van Wijngaarden RF, Festen DA, Otten BJ, et al. Bone mineral density and effects of growth hormone treatment in prepubertal children with Prader-Willi syndrome: A randomized controlled trial. J Clin Endocrinol Metab. 2009;94:3763-3771.
15. Colmenares A, Pinto G, Taupin P, et al. Effects on growth and metabolism of growth hormone treatment for 3 years in 36 children with Prader-Willi syndrome. Horm Res Paediatr. 2011;75:123-130.
16. Rubin DA, Cano-Sokoloff N, Castner DL, et al. Update on body composition and bone density in children with Prader-Willi syndrome. Horm Res Paediatr. 2013;79:271-276.
17. Höybye C, Hilding A, Jacobsson H, Thorén M. Metabolic profile and body composition in adults with Prader-Willi syndrome and severe obesity. J Clin Endocrinol Metab. 2002;87:3590-3597.
18. Butler MG, Haber L, Mernaugh R, Carlson MG, Price R, Feurer ID. Decreased bone mineral density in Prader-Willi syndrome: Comparison with obese subjects. Am J Med Genet A. 2001;103:216-222.
19. Vestergaard P, Kristensen K, Bruun JM, et al. Reduced bone mineral density and increased bone turnover in Prader-Willi syndrome compared with controls matched for sex and body mass index-a crosssectional study. J Pediatr. 2004;144:614-619.
20. Butler JV, Whittington JE, Holland AJ, Boer H, Clarke D, Webb T. Prevalence of, and risk factors for, physical ill-health in people with Prader-Willi syndrome: A population-based study. Dev Med Child Neurol. 2002;44:248-255.
21. Jørgensen AP, Ueland T, Sode-Carlsen R, et al. Two years of growth hormone treatment in adults with Prader-Willi syndrome do not improve the low BMD. J Clin Endocrinol Metab. 2013;98:E753-E760.
22. Siemensma EP, de Lind van Wijngaarden RF, Otten BJ, de Jong FH, Hokken-Koelega AC. Testicular failure in boys with Prader-Willi syndrome: Longitudinal studies of reproductive hormones. J Clin Endocrinol Metab. 2012;97:E452-E459.
23. Siemensma EP, van Alfen-van der Velden AA, Otten BJ, Laven JS, Hokken-Koelega AC. Ovarian function and reproductive hormone levels in girls with Prader-Willi syndrome: A longitudinal study. J Clin Endocrinol Metab. 2012;97:E1766-E1773.
24. Festen DA, de Lind van Wijngaarden R, van Eekelen M, et al. Randomized controlled GH trial: Effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome. Clin Endocrinol. 2008;69:443-451.
25. Lo ST, Siemensma EP, Festen DA, Collin PJ, Hokken-Koelega AC. Behavior in children with Prader-Willi syndrome before and during growth hormone treatment: A randomized controlled trial and 8-year longitudinal study. Eur Child Adolesc Psychiatry. 2014 Dec 19. [Epub ahead of print]
26. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Archives of disease in childhood. 1976;51:170-179.
27. Deal CL, Tony M, Höybye C, et al. Growth Hormone Research Society workshop summary: Consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab. 2013;98:E1072-E1087.
28. Kröger H, Vainio P, Nieminen J, Kotaniemi A. Comparison of different models for interpreting bone mineral density measurements using DXA and MRI technology. Bone. 1995;17:157-159.
29. Boot AM, Bouquet J, de Ridder MA, Krenning EP, de Muinck Keizer-Schrama SM. Determinants of body composition measured by dual-energy X-ray absorptiometry in Dutch children and adolescents. J Clin Nutr. 1997;66:232-238.
30. van der Sluis IM, de Ridder MA, Boot AM, Krenning EP, de Muinck Keizer-Schrama SM. Reference data for bone density and body composition measured with dual energy x ray absorptiometry in white children and young adults. Arch Dis Child. 2002;87:341-347; discussion 341-347.
31. Fredriks AM, van Buuren S, Burgmeijer RJ, et al. Continuing positive secular growth change in The Netherlands 1955-1997. Pediatr Res. 2000;47:316-323.
32. Mul D, Fredriks AM, van Buuren S, Oostdijk W, Verloove-Vanhorick SP, Wit JM. Pubertal development in The Netherlands 1965-1997. Pediatr Res. 2001;50:479-486.
33. van der Sluis IM, Boot AM, Hop WC, et al. Long-term effects of growth hormone therapy on bone mineral density, body composition, and serum lipid levels in growth hormone deficient children: A 6-year follow-up study. Horm Res. 2002;58:207-214.
34. Carrel AL, Allen DB. Effects of growth hormone on body composition and bone metabolism. Endocrine. 2000;12:163-172.
35. Siemensma EP, de Lind van Wijngaarden RF, Otten BJ, de Jong FH, Hokken-Koelega AC. Pubarche and serum dehydroepiandrosterone sulphate levels in children with Prader-Willi syndrome. Clin Endocrinol. 2011;75:83-89.
36. Ho-Pham LT, Nguyen UD, Nguyen TV. Association between lean mass, fat mass, and bone mineral density: A meta-analysis. J Clin Endocrinol Metab. 2014;99:30-38.
37. Högler W, Briody J, Woodhead HJ, Chan A, Cowell CT. Importance of lean mass in the interpretation of total body densitometry in children and adolescents. J Pediatr. 2003;143:81-88.
38. Ross JL, Quigley CA, Cao D, et al. Growth hormone plus childhood low-dose estrogen in Turner's syndrome. N Engl J Med. 2011;364:1230-1242.
39. Kodama M, Komura H, Kodama T, Nishio Y, Kimura T. Estrogen therapy initiated at an early age increases bone mineral density in Turner syndrome patients. Endocr J. 2012;59:153-159.
40. Baroncelli GI, Bertelloni S, Sodini F, Saggese G. Longitudinal changes of lumbar bone mineral density (BMD) in patients withGH deficiency after discontinuation of treatment at final height; timing and peak values for lumbar BMD. Clin Endocrinol. 2004;60:175-184.
41. Conway GS, Szarras-Czapnik M, Racz K, et al. Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency. Eur J Endocrinol. 2009;160:899-907.
42. Saggese G, Baroncelli GI, Vanacore T, Fiore L, Ruggieri S, Federico G. Indications and strategies for continuing GH treatment during transition from late adolescence to early adulthood in patients with GHdeficiency: The impact on bone mass. J Endocrinol Invest. 2004;27:596-602.